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Abstract
Autopsy studies of adults dying of non-cancer causes have shown that virtually all of us possess occult, cancerous lesions.
This suggests that, for most individuals, cancer will become dormant and not progress, while only in some will it become
symptomatic disease. Meanwhile, it was recently shown in animal models that a tumor can produce both stimulators and
inhibitors of its own blood supply. To explain the autopsy findings in light of the preclinical research data, we propose a
mathematical model of cancer development at the organism scale describing a growing population of metastases, which,
together with the primary tumor, can exert a progressively greater level of systemic angiogenesis-inhibitory influence that
eventually overcomes local angiogenesis stimulation to suppress the growth of all lesions. As a departure from modeling
efforts to date, we look not just at signaling from and effects on the primary tumor, but integrate over this increasingly
negative global signaling from all sources to track the development of total tumor burden. This in silico study of the
dynamics of the tumor/metastasis system identifies ranges of parameter values where mutual angio-inhibitory interactions
within a population of tumor lesions could yield global dormancy, i.e., an organism-level homeostatic steady state in total
tumor burden. Given that mortality arises most often from metastatic disease rather than growth of the primary per se, this
finding may have important therapeutic implications.
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Introduction
Almost all of us carry small tumor lesions that for many will not
progress to symptomatic disease. Indeed, as evidenced in autopsy
studies for adults without pre-established cancer such as [1,2],
occult lesions are present in most healthy adults. Nielsen et al. [3]
found that, out of 110 women cases, among which only one had
been previously treated for breast cancer, 22% had at least one
malignant lesion. Moreover, 45% of these had multicentric lesions.
Similar results have been reported for prostate cancer in men [4].
For thyroid cancer, autopsy results [2] showed a prevalence rate of
99.9% for occult carcinomas, while incidence of thyroid cancer is
only 0.1% [5].
To explain these results, it is necessary to understand the tumor
dormancy phenomenon. Tumor dormancy [6,7] is defined by
stable or very slow tumor growth. It can happen at the cellular
level as a malignant cell remaining quiescent for a long period
before awakening, but here we focus on the mm-scale lesions such
as have surfaced in the several remarkable autopsy studies
discussed, i.e., tissue-level tumor dormancy. Although the sizes
of these dormant tumors remain almost constant, it is not due to a
cessation in cell proliferation, but rather to increased apoptosis
that leads to a near zero net growth rate [6–8]. Clinically, tumor
dormancy has been observed in breast cancer [3,9–11], melanoma
[12] and prostate cancer [4], among many others [6]. Dormancy is
particularly relevant to the situation where secondary tumors
(metastases) remain small and undetectable for extended periods.
Various explanations have been proposed for tumor dormancy,
among these being the achievement of a balance between
stimulation and inhibition of angiogenesis [7,13,14]. This mech-
anism offers one explanation for how secondary tumors may be
suppressed to a near-dormant state by the primary; a phenomenon
known as ‘concomitant resistance’ [15,16]. In fact, a number of
explanations for the concomitant resistance phenomenon have
been suggested, as well summarized by Chiarella et al. [16]: 1)
monopolization of certain resources by the primary tumor that
deprives secondary tumors of materials needed for growth, 2)
primary tumor-induced enhancement of immune suppression of
small secondary tumors (concomitant immunity), 3) anti-prolifer-
ative molecules released by the primary tumors and 4) release of
angiogenesis inhibitors by the primary tumor into the blood
circulation resulting in inhibition of vascular development at
secondary sites. Nevertheless, although a distant impairment of
metastatic growth by a primary tumor has been recognized for
over a hundred years [17], and has meanwhile been informed by
various preclinical [18–22] and clinical [9,23–25] studies, it
remains poorly understood.
However, because of evidence that concomitant resistance
happens in immune-deficient mice [21] and considering the large
and unequivocal body of support for the role angiogenesis
inhibition plays in the maintenance of tumor dormancy [8,26–
30] and the ‘‘angiogenic switch’’ [31] in escape from dormancy,
our focus here will be on the last theory. Angiogenesis, the process
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of creating new blood vessels and developing a supporting vascular
network, was shown by Folkman [32] to be critical for tumor
growth. Indeed, without development of new blood vessels, a
malignant neoplasm cannot grow further than about 2 to 3 mm in
diameter, due to nutrient supply limitations [32]. This process is
regulated by the release from cancer cells of stimulatory growth
factors, such as vascular endothelial growth factor (VEGF), that
induce proliferation, migration and maturation of surrounding
endothelial cells, as well as the production of angiogenesis
inhibitory factors that act to curtail endothelial expansion [33].
As an example, in 1994 when examining the growth of Lewis lung
carcinoma in a syngeneic murine tumor model, O’Reilly et al. [26]
discovered an endogenous molecule having an inhibitory effect on
angiogenesis, which they called ‘angiostatin’, followed soon by the
discovery of ‘endostatin’ [27]. Endogenous anti-angiogenic mol-
ecules were also evidenced in human cancer, an example being
thrombospondin-1 [29]. Overlaying the ability of tumors to
stimulate vasculature, the discovery of their ability to also inhibit it
[34] allows for the possibility that tumors may indirectly control
their own growth [14,33,34], perhaps as a vestige of normal organ
growth control. Further, inherent to this self-control notion, if the
inhibitors were longer-lived and thus more persistent in the
circulation, they could have the collateral effect of suppressing
angiogenesis and growth at distant metastatic sites as the tumor
mass gets large [14]. Indeed, the half-life of angiogenesis
stimulators has been reported to be on the order of minutes for
VEGF [35], while that for angiogenesis inhibitors is on the order
of hours [26,29].
Amidst these developments, there have been a number of efforts
to take numerous complex mechanisms of cancer biology into
account in mathematical models (see [36] for a review), but very
few of these models have had the aim of describing metastatic
development, despite metastasis being the main cause of death
from cancer [37]. Indeed, while the cure rate of cancer before
appearance of metastases is about 90% for all cancers combined, it
falls to just 15% when distant metastases are present at diagnosis
[16]. As far as we know, modeling efforts in this direction can only
be found in the work of Liotta and coworkers [38], and more
recently in a few stochastic models [39–42] describing progression
through the different stages of the metastatic process (cell
detachment, intravasation, survival in the blood, extravasation,
settling in a new environment), and in one notable dynamic model
[43]. In this last case, Iwata and coworkers [43] proposed a
quantitative formalism for the development of metastatic colonies,
which was of great potential interest as it is was designed to
describe the size distribution of the metastases, allowing thus to
distinguish between micro-metastases and larger lesions. However,
this model does not take angiogenesis into account. We therefore
decided to theoretically combine this work with that of Hahnfeldt
et al. [14] for tumor development under angiogenic control, along
with a mathematical model developed for the growth and
dissemination of a metastatic population [44,45]. The goal we
realized was a new global formalism that integrates local
stimulation with systemic inhibition of angiogenesis by a circulat-
ing factor produced by each lesion in a population of tumors, to
provide insight into the development of the entire tumor/
metastasis system.
Methods and Results
In silico model – derivation and implementation
The global philosophy of the model we propose is to consider
the development of cancer disease at the organism scale, by
describing the colonization and dissemination of a population of
secondary tumors (metastases), in parallel with the growth of the
primary lesion, taking into account organism-scale signaling
interactions amongst these various tumor sites. The impetus for
this viewpoint comes from Iwata et al. [43] where the authors
derived a structured population model for describing the
metastatic colonies represented by a density structured in size
(volume). This model consists of a linear transport partial
differential equation with a nonlocal boundary condition of
renewal type. It has been further mathematically studied in
[46,47], in particular to develop efficient numerical methods for
discretizing the problem.
A major limitation of this approach, though, is that it does not
take angiogenesis into account, although this is a fundamental
process of tumor development that cannot be neglected, partic-
ularly if we want to study the effects of clinical angiogenesis
inhibition. However, by combining the approach of Iwata et al.
[43], arguably the first dynamical model for metastatic develop-
ment, along with the model of Hahnfeldt et al. [14], which is the
first to consider angiogenic homeostatic control of tumor growth,
we developed in previous work a hybrid construct that integrates
the angiogenic process into the growth of each tumor [44,45,48].
Since this model was written at the level of the organism, it was
considered a suitable framework to adapt to the problem of
analytically describing the consequences of systemic inhibition of
angiogenesis (SIA).
The result is a model for tumor growth control that takes into
account the local and systemic actions of angiogenesis regulators.
It integrates the ability of tumor lesions to locally stimulate
angiogenesis while simultaneously inhibiting angiogenesis globally,
and is fitted to preclinical data. Information on the behavior of
metastases is inferred from the estimated parameters. Simulations
of the cancer history are performed, which provide a detailed
description of the distribution of predicted metastatic lesion sizes.
The biological hypothesis of a global dormancy state of self-
inhibiting tumors is then tested, and corresponding ranges of the
inhibitor production rate identified.
A schematic view of the new formalism we propose is presented
in Figure 1. The main feature added to the previous model
(Benzekry [48]) is a new variable representing the circulating
concentration of an endogenous angiogenesis inhibitor, standing in
for all possible inhibitory molecules (examples being endostatin,
angiostatin or thrombospondin-1) impacting on the growth of each
tumor. As a general modeling principle, we sought to be
parsimonious and describe the major dynamics of the system with
as few parameters as possible to assure each dynamic introduced
carries its proper burden to explain the data.
Mathematics of tumor growth and systemic inhibition of
angiogenesis
Our construct considers primary tumors and their metastases to
be distinct lesions whose states are described by two traits: volume
V and carrying capacity K. The primary tumor state is denoted
(Vp(t), Kp(t)). The model’s main variable is r(t, V, K), the
physiologically structured density of metastases having volume V
and carrying capacity K at time t. The term density means that the
metastases are assumed to exist in a continuum of sizes and
carrying capacities and that the number of tumors between
volumes V1 and V2 and carrying capacities between K1 and K2 is
given by
ÐV2
V1
ÐK2
K1
r(t,V ,K)dVdK . We assume that the dynamics of
each tumor’s state are governed by a growth rate for (V, K),
denoted by the vector G(V, K; Vp, r), that dissemination of new
metastases is driven by a volume-dependent emission rate b(V),
and that the repartition of metastases at birth is given by N(V, K).
Dormant Metastases from Angiogenesis Inhibition
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The precise expressions of these functions will be described below.
We consider some fixed final time T and a physiological domain V
for the possible values of (V, K), defined as V= (V0, +‘)6(0, +‘)
where the distribution of metastases has its support, which means
that metastases have size bigger than the size of one cell V0 and
non-negative carrying capacity. In the formula below, the vector
n(V, K) stands for the external unit normal to the boundary hV of
the domain V. The notation hV+ stands for the subset of the
boundary where the flux is pointing inward, i.e. where G(V, K; Vp,
r) N n(V, K),0. The map (V, K).r0(V, K) denotes the initial
distribution of the metastatic colonies.
Overall, the model we arrived at is a nonlinear transport partial
differential equation of renewal type with a nonlocal boundary
condition.
Ltrz div(rG)~0 (0,T)|V
{G(V ,K ;Vp,p).n(V ,K)r(t,V ,K)~N(V ,K)
ð
V
b(V )r(t,V ,K)dVdKzb(Vp(t))
8<
:
9=
; (0,T)|LVz
r(0,V ,K)~r0(V ,K) V
9>>>>>>=
>>>>>>;
ð1Þ
We now make precise the expressions of the various coefficients
of the model; in particular how the growth rate G is affected by the
total population of tumors represented by r. We assume that all
the tumors (primary and secondaries) share the same growth
model but have different parameters, due to the different sites
where they are located. However, within the population of
metastases, all tumors are assumed to grow with the same
parameters. The growth velocity of each tumor is given by a vector
field G(V, K; Vp, r). Following the approach of [14] we assume
G(V , K ;Vp,r)~
aV ln
K
V
 
Stim(V , K){Inhib(V , K;Vp,r)
0
@
1
A:
In the previous expression, the first line is the rate of change of
the tumor volume V (where a is a constant parameter driving the
proliferation kinetics of the cancer tissue) and the second line is the
rate of change of the carrying capacity K. The main idea of this
tumor growth model is to start from a gompertzian growth of the
tumor volume (or any carrying capacity-like growth model [49])
and to assume that the carrying capacity K is a dynamical variable
representing the tumor environment limitations (here limited to
the vascular support) changing over time. The balance between a
stimulation term Stim(V, K) and an inhibition term Inhib(V, K; Vp(t),
r(t, V, K)) governs the dynamics of the carrying capacity. For the
stimulation term we follow [14] and assume
Stim(V , K) ~ bV ,
where the parameter b is related to the concentration of angiogenic
stimulating factors such as VEGF. This last quantity was derived
to be constant in [14] from the consideration of very fast clearance
of angiogenic stimulators [35].
For the inhibition term, Hahnfeldt et al. [14] only considered a
local inhibition coming from the tumor itself. Our main modeling
novelty is to consider in addition a global inhibition coming from
the release in the circulation of angiogenic inhibitors by the total
(primary + secondary) population of tumors. The following is an
extension of the biophysical analysis performed in [14]. Let us
consider a spherical tumor of radius R inside the host body. The
host is represented, for simplicity, by a single compartment of
volume Vd in which concentrations are assumed spatially uniform.
Let n(r) be the inhibitor concentration inside the tumor at radial
distance r. Let the intra-tumor clearance of inhibitors, known to be
Figure 1. Schematic representation of the model for systemic inhibition of angiogenesis. m, a: metastatic spreading parameters. p:
production rate of angiogenesis inhibitor. e: efficacy parameter of inhibitor. k: elimination rate of the inhibitor.
doi:10.1371/journal.pone.0084249.g001
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slow, be (approximately) zero [14]. At quasi steady state, n(r) then
solves the following diffusion equation:
n’’(r)z
2n’(r)
r
z
p
D2
~0,
where p is the inhibitor production rate and D2 is the inhibitor
diffusion constant. This equation has the boundary condition
n(R) = i(t; Vp, r(t, V, K)), where the expression on the right
represents the systemic concentration of the inhibitor resulting
from a primary tumor volume Vp and secondary tumors of density
r at time t. Solving this equation (using that n(0),+‘) we obtain
n(r) ~ i z
p
6D2
R2{r2
 
:
From this expression we compute the mean inhibitor concen-
tration in the tumor to obtain
Inhib V , K ; Vp,p
 
~ e^ i z
p
15D2
R2
 
K ~
e^ i z
p
15D2
3
4p
 2
3
V
2
3
 !
K ,
where e^ is a sensitivity coefficient. For i(t; Vp, r(t, V, K)), considering
that the total flux of inhibitors produced by a tumor with volume V
is pV and assuming that the inhibitor production rate is the same in
all the tumors, we have
Vd
di
dt
~ pVp z
ð
V
pVr(t,V , K)dVdK { kVdi,
where k is an elimination constant from the blood circulation.
Setting I(t; Vp, r(t, V, K)) =Vdi(t; Vp, r(t, V, K)), we get
dI
dt
~ pVp z
ð
V
pVr(t,V , K)dVdK { kI ,
which has an initial condition that in significant cases may be set to
zero, i.e., I(t=0) = 0. Overall, the explicit expression of the
metastases growth rate is given by
G(V , K ; Vp, r) ~
aV ln
K
V
 
bV{dV
2
3K{eIK
0
B@
1
CA, ð2Þ
where e~
e^
Vd
and
d ~ eVd
p
15D2
3
4p
 2
3
: ð3Þ
Note that we retrieve here the local term dV2/3 from the analysis
of [14]. Our analysis results in an additional global term eI that
captures the effect of systemic inhibition of angiogenesis.
For the primary tumor, we assume the same structural growth
model. The dynamics of (Vp, Kp) are thus given by
d
dt
Vp
Kp
 
~ Gp Vp, Kp; Vp,r(t,V , K)
  ð4Þ
where Gp has the same expression as G, except that the parameters
ap and bp (the values of a and b that are associated with the function
G for the primary) may be different from a and b associated with
metastases, in those cases where the primary and metastases are
presumed to have different growth kinetics. The inhibitor
production rate p and effect of the inhibitor e are assumed to be
the same for the primary and secondary tumors, which implies
same value also for d in view of formula (3).
Metastatic dissemination
There is no clear consensus in the literature about metastases
being able to metastasize or not [50–52]. However, we argue here
that cancer cells that have acquired the ability to metastasize
should conserve it when establishing a new site. Moreover, since
metastases remain undetectable for an extended time [50–52] (in
particular because tumors could remain dormant for some time),
the absence of clear proof in favor of metastases from metastases
could be due to the short duration of the experiments compared to
the time required for a second generation of tumors to reach a
visible size. Here we are interested in long-time behaviors and,
although metastases from metastases could be neglected to a first
approximation, we think this second-order term is relevant in our
setting and chose to include it in our modeling, in light of some
clinical evidence supporting second-generation metastases [53].
Successful metastatic seeding results when one malignant cell is
able to overcome various adverse events including: detachment
from the tumor, intravasation, survival in the blood/lymphatic
circulation, escape from immune surveillance, extravasation,
survival in a new environment (see [54] for more details about
the biology of the metastatic cascade). Here, we regroup all these
events into one emission rate b(V, K), quantifying the number of
successfully newly created metastases per unit of time. We assume
very small metastases do not metastasize because they do not have
access to the blood circulation, accounted for here by including a
threshold Vm below which tumors do not spread new individuals.
Vm is taken here to be 1 mm
3 as an approximation of the volume
at which the angiogenic switch happens [32]. Apart from the
addition of this threshold, the expression chosen for b is the same
as that used by Iwata et al. [43]:
b(V , K) ~ b(V ) ~
mV a if V§Vm
0 otherwise

ð5Þ
where m and a are coefficients quantifying the overall metastatic
aggressiveness of the cancer disease. The parameter m represents
the intrinsic metastatic potential of the cancer cells, and a
represents the microenvironmental component of metastatic
dissemination. It lies between 0 and 1 and is the third of the
fractal dimension of the tumor vasculature, assumed here to be the
same for all tumors. For instance, if vasculature develops
superficially, then a=2/3, whereas for a fully penetrating
vasculature, the value would be a=1. We here assume the
dissemination rate depends only on the volume because simula-
tions revealed that adding a monotone dependence on K did not
improve the flexibility of the model even while adding at least one
parameter, contrary to the parsimony principle.
Stating a balance law for the number of metastases when they
are growing in size gives the first equation of (1). The boundary
condition, i.e. the second equation of (1), states that the entering
Dormant Metastases from Angiogenesis Inhibition
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flux of tumors equals the newly disseminated ones. These result
from two sources: spreading from the primary tumor, modeled by
the term bVp(t), and second-generation tumors coming from the
metastases themselves, described by the termÐ
V
b(V )r(t,V , K)dVdK. The map (V, K).N(V, K), where (V, K) M
hV, stands for the volume- and carrying-capacity-dependent
distribution of metastases at birth. Assuming that newly created
tumors all have the size of 1 cell, denoted by V0, and some initial
carrying capacity, denoted by K0, we have
N(V , K)~ d(V ,K)~(V0,K0) ð6Þ
i.e. the Dirac distribution centered in (V0, K0). We have previously
discussed how this form can be deduced by passing to the limit
from an absolutely continuous density [55]. An important feature
of this model, in contrast to previous no-SIA models, is that we
allow metastases to exit the domain by imposing the boundary
condition only where the flux points inward and letting tumors exit
the domain in the opposite situation. In view of expression (2), this
occurs when the carrying capacity K is less than the volume of one
cell, V0, i.e. when global inhibition is strong enough so that tumors
can cross the line K=V0, which is the case when G(V0,
V0)N(0,1) = bV0{dV0
2
3{eIV0v0. These tumors are then removed
from the population, corresponding to death caused by nutrient
deprivation.
From the solution r of the model (1,3–6), biologically relevant
macroscopic quantities can be defined, such as the total number of
metastases N(t)~
Ð
V
r(t,V , K)dVdK, the total metastatic burden
M(t)~
Ð
V
Vr(t,V , K)dVdK, or the mean size of the metastases
M(t)
N(t)
.
Solution-finding
To approximate the solutions of the problem (1,3–6) we adapted
a numerical procedure previously developed for the model without
SIA in [45,55]. It is a Lagrangian scheme based on the
straightening of the characteristics of the transport equation. We
then used an Euler method for discretization of the characteristics
and computation of the primary tumor ordinary differential
equation. The integral in the boundary condition was computed
using the trapezoid approximation method.
Parameters surmised from existing preclinical data
Data on metastatic development are not common in the
literature, especially for micrometastases or dormant tumors, since
these measurements are technically difficult to obtain. Even more
difficult to find are data quantifying systemic inhibition of
angiogenesis. For our purpose we use data from Huang et al. [56]
that do not explicitly deal with systemic inhibition of angiogenesis
nor global dormancy, but where number and mean size of
metastases at the end time (T=32 days) are available, together
with primary tumor growth kinetics. The cell line used in this work
is a spontaneous mouse breast cancer line 4T1, known to be highly
metastatic with relatively slow primary tumor growth. Cells were
injected subcutaneously (105 cells) in BALB/c mice. As shown in the
following, our model was able to explain these experimental data.
Values of the parameters were fixed either by direct extraction
from the literature, heuristic derivation, or by fitting the model to
the data from [56]. For the preclinical data that we used,
metastases actually develop to symptomatic volumes and did not
evidence manifest global inhibition. Hence for fitting of the model,
we consider SIA as being negligible and take I=0. The parameter
estimation we performed here is only intended for estimation of
growth and metastatic spreading parameters. The assumption of
negligible SIA was found a posteriori to be adequate for description
of the data from [56], because adding an SIA term with reasonable
parameter values did not have any impact on the model
simulations, in the framework of the experiment from [56]. In
the context of no SIA, there is no impact of the metastases on the
primary tumor and we could separately fit the primary tumor
growth and the metastatic development. This approach (compared
to a global fitting of all the parameters together) further reduces
the parameterization of the model and allows for more stable and
biologically relevant parameter estimation. Indeed, only two
degrees of freedom were used to fit the primary tumor growth
(seven time points) and two for the data on metastases (two
measurements). The meaning, units and values of the model
parameters resulting from the whole estimation procedure are
summarized in Table 1.
In Hahnfeldt et al. [14], values for the elimination rates k and
efficacy constants e for two endogenous angiogenesis inhibitors,
endostatin and angiostatin, were estimated by fitting tumor growth
data of mice that received injections of these anti-angiogenic
agents. We focus here on angiostatin, and use values for the agent
efficacy e and the elimination rate k from the blood circulation
reported in Hahnfeldt et al. [14], applying these to a 20 g mouse.
This value gives a half life for angiostatin of 1.8 days, which is
consistent with the value of 2.5 days that can be found in the
literature [26].
O’Reilly et al. [26] showed that injection of 12.5 mg per day of
recombinant human angiostatin reproduces the systemic inhibi-
tion due to a primary tumor removed when it reached the size of
1500 mm3. An approximation of the production rate in their
setting is p&
12:5
1500
|10{3&8:3|10{6 mg.mm23.day21. For the
value of Vd we argue that the blood volume of a mouse is about
1.2–1.6 cm3 per 20 g body weight. Taking an approximate value
of 1.4 cm3 and assuming that the interstitial (extracellular) space
fills 30% of the extravascular space (in agreement with measure-
ments of the fraction of volume occupied by cells), summing the
interstitial space and blood volume gives 6.98 cm3. Hence we took
Vd=7000 mm
3 to be an approximation of the distribution volume.
For the diffusion coefficient of angiostatin, D2, we used a value
1.56 mm2day21 taken from the literature [57]. Based on these
values and the formula (3) for d derived in the modeling section, we
were able to heuristically compute an approximation of the
parameter d as d<0.0717 mm22day21. In the following, we fixed
d and dp to this value, which allowed us to reduce possible
indeterminacy in the parameter estimation for the growth model.
When reproducing the experiment of Huang et al. [56], we
fixed the initial size of the primary tumor to be Vp(0) = 0.1 mm
3
(corresponding to 105 cells, i.e. the number of cells injected into
the mouse) and arbitrarily set the initial carrying capacity of the
primary tumor to Kp(0) = 200 mm
3. Metastases were assumed to
start with initial size V0 = 1 cell = 10
26 mm3 and initial carrying
capacity K0 = 1 mm
3 (assumed to be an approximation of the
maximum reachable size without angiogenesis [32]). For meta-
static emission, we considered a superficial vascular development
and took a=2/3, following what was estimated in Iwata et al. [43]
from clinical data.
Fits to the data
Parameters ap and bp were obtained by minimizing the sum of
squared errors between the tumor growth model simulation and
the primary tumor growth data from [56]. Least squares
Dormant Metastases from Angiogenesis Inhibition
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e84249
minimization was performed using the trust region reflective
algorithm implemented in Matlab (Matlab 2009b, The Mathworks
Inc.). We obtained good agreement between the fit and the data
(Figure 2). Goodness of fit quantification by the R2 value
(R2~1{
P
(yi{f (ti))
2P
(yi{y)
2
, where the yi are the data points, y is
the mean value of the data and the f(ti)’s are the values of the
model at times ti) gave an excellent score of R
2 = 0.99.
Assuming that differences in growth between the primary tumor
and its metastases should arise from interactions with the
microenvironment, we fixed the proliferation parameter a for
the metastases to the value obtained for the primary tumor
growth. The only remaining parameters to be fixed were then b
(driving the angiogenic stimulation) and m (controlling metastatic
dissemination), allowing us to minimize the overall parameteriza-
tion of the model (two parameters for two data points). These last
two coefficients were determined by fitting the model to the
experimental metastatic data of Huang et al. [56], the results of
which are reported in Table 2. We obtained good agreement to
the number and mean size of metastases. It was determined that
with the estimated value of m a tumor of 200 mm3 spreads a new
metastasis every 0.77 days.
The parameter estimation that we performed allowed us to
simulate the experiment of [56] by using the parameters resulting
from the model’s fit (and I=0). This gave further insight beyond
the mere availability data could provide on the time development
dynamics of the metastases and their final size distribution.
Figure 3.A shows the growth in time of the total metastatic burden,
while Figure 3.B depicts the colony size distribution at T=32 days
for an in silico replicate of the experiment performed in [56]. It
reveals a nontrivial size distribution of the final metastatic colonies
with a mode between 0.01 and 0.1 mm3, and only one tumor with
size larger than 10 mm3. At this time the total lung metastatic
burden is 63.5 mm3 distributed between 48.5 tumors. Simulation
performed with a non-zero I and a value for p extracted from [26]
(see above) presented no significant difference in this setting
compared to the simulation with I=0, hence justifying a posteriori
our assumption of negligible effect of SIA in the setting of [56].
These simulations and parameter estimation show that our
mathematical model is a possible theory describing growth and
development of primary and secondary tumors in a 4T1 cell line
model. While in this context, systemic inhibition of angiogenesis had
no significant importance in the small time range, it was concluded
more broadly that the model, endowed with adequate parameter
values, should be a useful theoretical tool for investigating a range of
situations beyond the experimental setting of [56].
Simulation of the cancer history from the first cancer cell
predicts uncontrolled metastatic burden
Using our model and based on the parameters estimated in the
previous section (Table 1), we were able to extrapolate to a totally
Table 1. Values, units and meaning of the model parameters.
Parameter Value Unit Meaning Rationale
ap 0.154 day
21 PT cells proliferation Fit PT
bp 16.7 day
21 PT angiogenic stimulation Fit PT
dp 0.0717 mm
22 day21 PT angiogenic local inhibition H
a 0.154 day21 Met cells proliferation Fit Met
b 12.5 day21 Met angiogenic stimulation Fit Met
d 0.0717 mm22 day21 Met angiogenic local inhibition H
m 0.0229 mm23day21 Colonization rate Fit Met
a 2/3 Fractal dimension of vascularization [43]
p 8.361026 mg mm23 day21 Production of I [26]
k 0.38 day21 Elimination rate of I [14]
e 7.5 mg21day21 Effect of I [14]
V0 10
26 mm3 Met initial volume H
K0 1 mm
3 Met initial carrying capacity [32]
Vm 1 mm
3 Threshold for metastatic emission H
D2 0.156 mm2day21 Angiostatin diffusion coefficient [57]
Vd 7000 mm
3 Distribution volume H
PT= Primary Tumor. Met =metastases. I = global amount of angiogenic inhibitor in the blood. H= heuristic derivation.
doi:10.1371/journal.pone.0084249.t001
Figure 2. Primary tumor growth. Comparison of the fit of the model
and the data from [56]. Data are mean + standard error.
doi:10.1371/journal.pone.0084249.g002
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new setting where the primary tumor starts with one cell instead of
an already large number of cells (approximately 105). In so doing,
we were able to simulate the whole cancer history, starting from
one initial cancerous cell (and initial carrying capacity of 1 mm3)
until the metastatic burden reached 5000 mm3, a burden we
considered potentially lethal for a mouse. The simulation
predicted this would happen 62.7 days after the first primary
tumor cancer cell. Time development of the primary tumor
volume, metastatic burden, total number and mean size of
metastases as well as inhibitor amount in the host are plotted in
Figure 4.
Interestingly, the model simulation predicts that the metastatic
burden would overcome the primary tumor mass, implying that
the mouse would probably die from growth of its secondary lesions
rather than from the initial tumor. This is consistent with the
metastatically aggressive phenotype of the 4T1 cell line. Quanti-
fication of the number of metastases reveals a final number of
about 217 tumors, lots of them being small (Figure 4C) and
probably undetectable in an experimental setting. Simulation with
the same set of parameters but neglecting the effect of SIA (I=0)
showed no detectable difference on this time frame. Significant
changes are observed later on, for volumes that are not considered
to be physiologically relevant. This confirms that for the 4T1 cell
line, metastases do develop and do not exhibit global dormancy,
even when SIA is present with the inhibitor production parameter
value extracted from [26]. Thus, based on biologically relevant
parameters, our simulation results suggest large growth of the
metastatic burden for the 4T1 cell line when starting from the first
cancer cell, with a final metastatic volume larger than the primary
tumor.
Higher production of systemic angiogenesis inhibitor
could result in long-term stable global dormancy in a
population of self-inhibiting metastases
The previous simulations used parameter values derived from
experimental data of a situation were metastases do develop and
grow, because this is the only case where metastases are
measurable and data are available. However we are interested
here in global dormancy and situations where the metastatic
population could remain ultimately small. We postulate that this
could happen when production of the angiogenesis inhibitor,
represented by parameter p in our model, is significantly higher.
Simulation results plotted in Figure 5 were obtained using a value
p=2.561024 mg.mm23day21, i.e., a value about 30 times that
extracted from [26]. From our previous modeling analysis and
formula (3), higher production of inhibitor also proportionally
increases the local inhibition parameters d and dp. In the
simulation reported in Figure 5, we kept all the other parameter
values unchanged from Table 1 and fixed the initial primary
tumor volume to Vp(0) = 1 cell and the initial primary tumor
carrying capacity to Kp(0) = 1 mm
3. We simulated the system over
a time of 350 days, covering the estimated lifespan of a mouse after
appearance of an initial malignant cell. We focused on asymptotic
behavior and possible convergence of the system to a steady state.
Table 2. Metastatic outputs.
Value from [56] Computed by the model
Median number of metastases (range) 43 (4–107) 43.03
Mean size of metastases in mm3 (range) 1.47 (1.30–1.66) 1.476
Comparison of the fit of the model and the data from [56]. For the number of metastases, the reported model value is the number of tumors above a minimal visible
size that we took to be 10 cells (tumors were counted using a dissecting microscope in [56]). Mean size was given as diameter in [56] and was converted here into
volume using V~ p
6
|D|w2, w~ 3
4
D.
doi:10.1371/journal.pone.0084249.t002
Figure 3. In silico simulation of the experiment from [56]. A. Time development of the metastatic burden. B. Colonies size distribution at the
end time T = 32 days (log-scale on the x-axis).
doi:10.1371/journal.pone.0084249.g003
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In Figure 5, the primary tumor volume, number and total burden
of the metastases, the time evolution of the global inhibitor
quantity and the size distribution of the metastases at the end time,
are plotted.
In this context, the first cancer cell initiates the disease by
growing and generating a first pool of metastases, but the
metastatic burden then quickly overshadows the growth of the
primary lesion (Figure 5.A). The primary tumor reaches a small
maximal size of 21.2 mm3 at time 82.9 days (Figure 5.A) and then
shrinks due to inhibition of angiogenesis provoked by the distant
metastases. There is a slowdown and eventual stabilization of the
metastatic burden, with a plateau value of about 2200 mm3. The
burden is composed of a large number of metastases (Figure 5.B),
most of them being occult micro-metastases as can be seen in the
final size distribution (Figure 5.C). This interesting feature of the
model simulation could be an in silico replicate of the aforemen-
tioned situations of cancer without disease [5]. In our model it
translates into an asymptotical steady state for the metastatic
burden while it is still composed of small lesions. The general
dynamics of the metastatic burden results from the balance of two
stimulating forces; growth and spread of new individuals,
competing with systemic inhibition of angiogenesis. Stimulation
depends on the parameters a and b, which capture the growth
process, and m and a, which capture spreading. Inhibition depends
on e and k, as well as on p, which controls the value of d. The
present values of the parameters generated long-term stabilization
of the mass. The size distribution of the population of secondary
tumors at time T=350 days is revealed to be non trivial, with
different numbers in the various size ranges. By 350 days, all the
metastases had volume lower than 10 mm3.
In sum, assuming substantial systemic inhibition of angiogenesis,
we theoretically obtained an in silico replicate of a situation in
which an important population of dormant micro-metastases
inhibiting each others’ growths is present, with a possibly non-
lethal final total metastatic burden. This situation was seen to
result when a 30-fold higher value for the inhibitor production
Figure 4. Simulation of the cancer history from the first cancer cell. Parameter values are the ones resulting from the fit to the data of [56],
reported in Table 1.
doi:10.1371/journal.pone.0084249.g004
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parameter p was used, compared to the case of growth of a breast
cancer line 4T1 extracted from the literature [26], where
unlimited expansion of the total metastatic burden was forecast.
Discussion
We propose an organism-scale model for the development of a
primary tumor and a population of secondary tumors that takes
into account systemic inhibiting interactions among tumors due to
the release of a circulating angiogenesis inhibitor. The model
proves to be able to describe in vivo data of primary tumor and
metastatic development and allows inference of information not
revealed by the experimental data, including the size density
distribution of metastases and their total number. Endowed with
biologically relevant parameter values, our model is a potentially
vital tool for the theoretical study of metastatic dynamics.
It was used here to investigate the whole cancer history from the
first cancer cell, and predicted that for the metastatically aggressive
4T1 cell line, metastases would grow unbounded for a physiolog-
ically relevant set of parameter values. In this case, the total
metastatic burden was found to become larger than the primary
tumor mass and probably would be responsible for death of the
animal. SIA effects were seen to be negligible in this context. A
higher production rate of the inhibitor, by contrast, could
theoretically make the primary tumor appearance and growth
only a transient event, giving way to a distinct process of tumor
development where, due to eventual self-inhibition of angiogenesis
at the organism scale, global dormancy is imposed on the entire
tumor/metastasis system, stabilizing the cancer disease. Our
analysis shows that SIA could conceivably create such a situation,
although it would require a very high value of the inhibitor
production rate – some 30-fold the value extracted from [26] –
which does not appear to be physiological. This suggests that SIA
alone is probably not sufficient to induce spontaneous global
dormancy and that other processes (such as immune effects) are
probably significantly involved. For now, however, our conclusions
Figure 5. Large time simulation for large inhibitor production (p=2.561024 mg.mm23.day21, d=2.16 mm22day21). The model
predicts stabilization of the metastatic burden to a situation where the whole metastatic population is in a global dormancy state.
doi:10.1371/journal.pone.0084249.g005
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are limited by the current lack of data on systemic inhibition of
tumor development. A study of interactions among multiple tumor
implants in controlled immune contexts could shed more light.
Meanwhile, these results inform the human situation by
providing elements of explanation for the high prevalence of
occult tumors found in autopsy studies. The results as well could
inform the consequences of chronic antiangiogenic intervention
[58]. As a case in point, progression of cancer disease in
individuals having a low production rate of inhibitor might be
forestalled, even outside an outright cure, by chronic external
administration of supplementary inhibitory agents that could
maintain an existing population of tumors in a global dormancy
state.
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